Investors

2015 News

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
11/25/15Forward Pharma Reports Third Quarter 2015 Financial and Operational Results
COPENHAGEN, Denmark, Nov. 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("We" or "Forward" or "Company"), today reported financial results for the third quarter ended September 30, 2015. Net loss for the third quarter ended September 30, 2015 was $15.8 million, or $0.34 per share versus $8.6 million, or $0.27 per share for the third quarter of 2014. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our third quarter net loss for 2015 would have b... 
Printer Friendly Version
09/08/15Forward Pharma Reports Second Quarter 2015 Financial and Operational Results
COPENHAGEN, Denmark, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("We" or "Forward" or "Company"), today reported financial results for the second quarter ended June 30, 2015. Net loss for the second quarter ended June 30, 2015 was $17.7 million, or $0.38 per share versus $3.2 million, or $0.10 per share for second quarter ended June 30, 2014. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our second quarter net loss for 2015 would have... 
Printer Friendly Version
09/01/15Forward Pharma CFO to Participate in Three Investor Conferences in September
COPENHAGEN, Denmark, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company's Chief Financial Officer, will participate in the following conferences: FBR's Second Annual Healthcare 1-on-1 Conference to be held at the Four Seasons in Boston, Massachusetts... 
Printer Friendly Version
06/19/15Forward Pharma CFO to Present at the JMP Securities Life Sciences Conference
COPENHAGEN, Denmark, June 19, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("Forward" or the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conference:    The JMP Securities Life Sciences Conference to be held at the St. Regis in New York, New Y... 
Printer Friendly Version
05/12/15Forward Pharma Reports First Quarter 2015 Financial and Operational Results
COPENHAGEN, Denmark, May 12, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("Forward" or the "Company"), today reported financial results for the first quarter ended March 31, 2015. Net income for the first quarter ended March 31, 2015 was $5.3 million, or $0.11 per share. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our first quarter net loss for 2015 would have been approximately $6.9 million, or $0.15 per share. The comparable amounts for 201... 
Printer Friendly Version
05/01/15Forward Pharma CFO to Present at Two Investor Conferences in May
COPENHAGEN, Denmark, May 1, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following investor conferences: The Deutsche Bank 40th Annual Health Care Conference to be held at the InterContinental Hotel in B... 
Printer Friendly Version
04/27/15Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Covers the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R) COPENHAGEN, Denmark, April 27, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company") announced today that the Company received a decision to grant from the European Patent Office (EPO) regarding its patent application 14172398.1 which covers, among other things, the treatment of multiple sclerosis with 480 mg per day of dimethyl fumarate (DMF) wherein the pH control... 
Printer Friendly Version
04/14/15U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Forward Receives Senior Party Status Based on Earlier Filing Date COPENHAGEN, Denmark, April 14, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company") announced today that an interference was declared by the Patent Trial and Appeal Board (PTAB) on April 13, 2015 between the Company's patent application 11/576,871 (the "'871 patent application") and Biogen's issued patent 8,399,514 (the "'514 patent"). The PTAB designated the Company as the "Senior Party" in the interference b... 
Printer Friendly Version
04/09/15Forward Pharma Pre-IPO Investors Voluntarily Agree to Extend Lock-Up
COPENHAGEN, Denmark, April 9, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company" or "Forward") announced today an agreement among all of its pre-IPO shareholders to voluntarily lock-up their shares for an additional 365 days beyond the expiration of the original IPO lock-up. These shareholders collectively account for over 75% of the Company's shares outstanding. The original lock-up agreement with the IPO underwriters expires on April 12, 2015. The new lock-up expires on Ap... 
Printer Friendly Version
03/25/15Forward Pharma Reports Fourth Quarter and Year End 2014 Financial and Operational Results
COPENHAGEN, Denmark, March 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), today reported financial results for the fourth quarter and year ended December 31, 2014. Net loss for the fourth quarter and year ended December 31, 2014 was $2.0 million and $19.0 million, respectively. Loss per share for the fourth quarter and year ended December 31, 2014 was $1.01 and $1.79, respectively, after accounting for a non-cash preferential distribution of approximately $42.7 million. As of Dece... 
Printer Friendly Version
03/16/15Forward Pharma CFO to Present at the Future Leaders Conference on March 20th
COPENHAGEN, Denmark, March 16, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conference: The BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference to be held at the Millennium... 
Printer Friendly Version
02/05/15Forward Pharma CFO to Present at Two Upcoming Conferences in February
COPENHAGEN, Denmark, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel Sendek, Forward Pharma's Chief Financial Officer, will present at the following conferences: The Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York, New York. Joel Sen... 
Printer Friendly Version